PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Sclerosing cholangitis

Drugs in development · updated 30 October 2026

Sclerosing cholangitis: drugs in development

As of 30 October 2026 there are 21 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for sclerosing cholangitis. 8 are experimental, that is not yet approved in the United States.

21Active trials
8Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
Norucholic acidIII1NCT06886360
BRS201II1NCT05835505
CS0159II1NCT05896137
HK-660SII1NCT06975150
HymecromoneII1NCT05295680
VolixibatII1NCT04663308
SiplizumabI1NCT06455280
TAK-781I1NCT07229911

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
ElafibranorIqirvo®III2NCT07387549
SimvastatinFlolipid®, Zocor®III1NCT04133792
VancomycinTyzavan®, Firvanq Kit®II5NCT07341282
FenofibrateFenoglide®, Antara (Micronized)®II1NCT06905054
MetforminRiomet Er®, Glumetza®II1NCT07898839
NemolizumabNemluvio®II1NCT07843420
UpadacitinibRinvoq Lq®, Rinvoq®II1NCT07678645
Amoxicillinamoxycillin, Moxatag®Early I1NCT06197308
RosuvastatinEzallor Sprinkle®, Crestor®Early I1NCT05912387

Sorted by most advanced phase and number of active trials.

All 17 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D015209 “Cholangitis, Sclerosing”.

ItalianoFrançaisDeutsch